What is it about?
Hypertension is a multifactorial pathology is one of the most important cardiovascular risk factors, affecting up to 30-40% of the general population. Complex immune responses are involved in the inflammatory mechanism of hypertension, with evidence pointing to increased inflammatory mediators even in prehypertensive patients. Chronic inflammation triggers endothelial dysfunction through proinflammatory cytokines. Increased serum level of proinflammatory cytokines in hypertensive patients has been associated with either increased blood pressure values and/or end-organ damage. Moreover, some cytokines (i.e., IL-6) seem to determine a hypertensive response to angiotensin II, regardless of blood pressure values.
Photo by Robina Weermeijer on Unsplash
Why is it important?
Understanding hypertension as an inflammatory-based pathology gives way to new therapeutic targets. As such, conventional cardiovascular drugs (statins, calcium channels blockers, and ACEIs/ARBs) have shown additional anti-inflammatory effects that could be linked to their blood pressure-lowering properties. Moreover, anti-inflammatory drugs (mycophenolate mofetil) have been shown to decrease blood pressure in hypertensive patients or prevent its development in normotensive individuals. Further research is needed to evaluate whether drugs targeting hypertensive-linked proinflammatory cytokines, such as monoclonal antibodies, could become a new therapeutic option in treating arterial hypertension.
Read the Original
This page is a summary of: Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?, International Journal of Hypertension, May 2019, Hindawi Publishing Corporation, DOI: 10.1155/2019/3159283.
You can read the full text:
The following have contributed to this page